表紙
市場調査レポート

組織工学および再生医療:各種技術と世界市場

Tissue Engineering and Regeneration: Technologies and Global Markets

発行 BCC Research 商品コード 228043
出版日 ページ情報 英文 171 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
組織工学および再生医療:各種技術と世界市場 Tissue Engineering and Regeneration: Technologies and Global Markets
出版日: 2014年08月08日 ページ情報: 英文 171 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2013年、世界の組織工学および再生医療の市場は170億ドルの市場規模を記録しました。2014年には208億ドルに近い規模に成長すると予測されており、その後は2019年まで22.3%のCAGRで推移し、2019年には569億ドルの規模に達すると予測されています。

当レポートでは、世界の組織工学および再生医療の市場について調査し、各種技術・材料・用途の種類と概要、技術・材料・用途・地域別の市場成長予測、市場成長への影響因子および市場機会の分析、将来の展望に関する分析、主要製品の詳細、競合環境の分析、主要企業のプロファイルなどを詳細に渡ってまとめています。

第1章 イントロダクション

第2章 サマリー

第3章 組織工学と組織の再生

  • 市場概要
  • 組織工学産業の進化と確実性
  • 組織工学による身体の一部の置換
  • 組織の再生のためのナノテクノロジー
  • 組織工学の将来の一部としての遺伝子治療
  • 幹細胞技術
  • 政府による法規制
  • ポーターのファイブフォース分析
  • 臨床試験
  • 市場力学

第4章 組織工学・組織再生市場の分析:技術別

  • 幹細胞技術
  • 幹細胞源
  • 細胞培養技術
  • 免疫受動化・免疫調節

第5章 組織工学・組織再生市場の分析:材料別

  • 合成材料
  • 生体由来材料
  • 遺伝子操作材料

第6章 組織工学・組織再生市場の分析:用途別

  • 内部臓器の再生
  • 中枢神経系の再生
  • 中枢神経系疾患のための再生
  • 心血管系疾患のための再生
  • 歯系組織の再生
  • 皮膚組織の再生
  • その他

第7章 組織工学・組織再生市場の分析:地域別

  • 北米
  • 欧州
  • その他の地域

第8章 競合環境

  • 承認
  • 各種契約・M&A
  • 新製品の投入・臨床試験

第9章 特許分析

  • 米国
  • 欧州
  • 日本

第10章 企業プロファイル

  • ADVANCED BIOHEALING
  • ADVANCED CELL TECHNOLOGY INC.
  • ARTERIOCYTE
  • ATHERSYS INC.
  • BIOHEART INC.
  • CERAPEDICS INC.
  • CO.DON AG
  • COOK MEDICAL INC.
  • CRYOLIFE INC
  • CYTOGRAFT TISSUE ENGINEERING
  • CYTOMEDIX INC.
  • CYTORI THERAPEUTICS INC.
  • GENZYME
  • KINETIC CONCEPTS INC.
  • MESOBLAST LTD.
  • ORTHOPEUTICS
  • WRIGHT MEDICAL TECHNOLOGY INC.

第11章 特許

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HLC101B

The global tissue engineering and regeneration market reached $17 billion in 2013. This market is expected to grow to nearly $20.8 billion in 2014 and $56.9 billion in 2019, a compound annual growth rate(CAGR) of 22.3%.

This report provides:

  • An overview of the global market for tissue engineering and regeneration, and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Information on the specific drivers, trends, and challenges for different segments of the market.
  • Valuable insight into future trends, details on products, and information on therapies available in the field of tissue engineering.
  • Analysis of the competitive environments, including new and potential markets for novel therapies and treatments.
  • Comprehensive profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF THE REPORT

This research report presents an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional markets. It includes key technologies involved in stem cell therapies and cell therapies. It analyzes the clinical trials and patents conducted in respective geographies. The report is an in-depth analysis of key companies operating in the global tissue engineering and regeneration market. It includes in-depth patent analysis that focuses on providing extensive technological trends across years and across regions, including the U.S., Europe and Japan.

The tissue engineering and regeneration market is mainly segmented into three classes: synthetic, genetically modified and biological materials. Synthetic materials are further categorized into biodegradable synthetic polymers, scaffold (medical poly lactic acid), artificial vascular graft materials and hydrogeltechnology. The biologically derived materials are segmented into, xenogenic tissue and collagen. The ablation device application market is further segmented on the basis of various applications for in-depth analysis of technology markets. The market study is detailed for application based on procedures, as well as its further implication on the therapeutic area. These two segments are also discussed in detailed for the forecast period. The market is segmented by region into the Americas, Europe, Asia-Pacific and ROW. Companies profiled in this report include Advanced Cell Technology, Arteriocyte, Athersys, Bioheart, BioMimetic Therapeutics, BioTissue Technologies, CeraPedics, Cook Biotech, CryoLife, Cytograft Tissue Engineering, Cytomedix, Cytori Therapeutics, Genzyme/Sanofi, Integra LifeSciences, International Stem Cell, LifeCell/Kinetic Concepts and Mesoblast.

ANALYST'S CREDENTIALS

Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life science market and the chemical domain. She has frequently delivered research services that include strategic recommendation and top business strategies to assist market players in making beneficial strategies. Ms. Jeevane holds a B.Sc degree in Biotechnology and a MBA degree in Marketing.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY AND OBJECTIVE
  • SCOPE OF THE REPORT
  • INTENDED AUDIENCE
  • INFORMATION AND METHODOLOGY SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, 2013-2019 ($ MILLIONS)

CHAPTER 3 TISSUE ENGINEERING AND REGENERATION

  • MARKET OVERVIEW
  • PROGRESS AND PROMISES FOR THE TISSUE ENGINEERING INDUSTRY
  • FIGURE 1 TISSUE-ENGINEERING STRATEGIES
  • REPLACING BODY PARTS THROUGH TISSUE ENGINEERING
  • NANOTECHNOLOGY FOR TISSUE REGENERATION
  • FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS
    • EFFECTS OF NANOTECHNOLOGY ON STEM CELL BEHAVIOUR FOR TISSUE REGENERATION
      • Nanoparticles
      • Nanoscaffolds
    • NANOTECHNOLOGY IN TISSUE REGENERATION APPLICATIONS
      • Bone and Cartilage Regeneration
      • Vascular Tissue Regeneration
      • Neural Tissue Regeneration
  • GENE THERAPIES AS PART OF THE FUTURE OF TISSUE ENGINEERING
    • PROGRESS
    • PROSPECTS
  • STEM CELL TECHNOLOGIES BOON TO TISSUE ENGINEERING
  • GOVERNMENT REGULATIONS AND LEGISLATIONS
    • U.S. AND EUROPEAN REGULATION FOR TISSUE ENGINEERING PRODUCTS
    • CHINESE REGULATION FOR TISSUE ENGINEERING
    • REGULATORY DIFFERENCES
    • TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE
    • ETHICAL ISSUES REGARDING STEM CELL THERAPIES AND CORD BLOOD BANKING
      • Ethical Issues Regarding Cord Blood Banking
      • Ethical Issues in Cord Blood Stem Cell Therapies
    • IMPACT OF THE HEALTHCARE SYSTEM ON TISSUE ENGINEERING MARKET DEVELOPMENT
    • TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, 2014
  • PORTER'S FIVE FORCE ANALYSIS OF THE TISSUE ENGINEERING AND REGENERATION MARKET
  • FIGURE 3 PORTER'S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS
    • SUPPLIER BARGAINING POWER: MODERATE
    • BUYER BARGAINING POWER: LOW
    • THREATS FROM SUBSTITUTE PRODUCTS: LOW
    • THREATS FROM NEW ENTRANTS: HIGH
    • COMPETETION FROM INDUSTRY PLAYERS: HIGH
  • CLINICAL TRIALS
    • U.S. TISSUE ENGINEERING CLINICAL TRIALS
    • TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING
      • Completed Clinical Trials for Tissue Engineering
      • TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING
      • Conclusion
      • Terminated Clinical Trials for Tissue Engineering
      • TABLE 5 U.S. TERMINATED CLINICAL TRIALS
      • Conclusion
    • EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING
    • TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING
      • Conclusion
  • MARKET DYNAMICS
    • DRIVERS
      • Emergence of Stem Cell Technology
      • FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2008-2012 (NO. OF TRIALS AND TREATMENTS)
      • Prominent Potential of Nanotechnology
      • Rise in Prevalence of Trauma Emergencies and Chronic Diseases
      • TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%)
      • Advancement in Surgical Technologies and Monitoring Devices
      • TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, 2007-2011
    • RESTRAINTS
      • Operational Inefficiency
      • Stringent Regulatory Policies and Ethical Issues
      • High Treatment Cost
    • STEM CELL APPLICATION OPPORTUNITIES
      • Classification of Stem Cells According to Their Ability to Differentiate
      • Getting Core Competency in Emerging Economies

CHAPTER 4 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY TECHNOLOGY

  • TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, THROUGH 2019 ($ MILLIONS)
  • STEM CELL TECHNOLOGIES
  • TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • STEM CELL SOURCES
    • STEM CELL EXTRACTION TECHNIQUES
    • ALTERED NUCLEAR TRANSFER
    • BLASTOMERE EXTRACTION
    • STEM CELL EXPANSION
    • STEM CELL DELIVERY
    • TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY
      • Direct Surgical Intramyocardial Injection
    • EXISTING AND DEVELOPMENT-STAGE STEM CELL PRODUCTS
    • TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 ($ MILLIONS)
      • Clinical Application of Stem Cell Technologies in the Commercial Market
        • Cardiovascular Repair
        • Neural Repair
        • Bone Repair
        • Skeletal Muscle Repair
        • Urologic Repair
  • CELL CULTURE TECHNOLOGIES
    • PROJECT NO. 1
      • Project Description
    • PROJECT NO. 2
      • Project Description
    • PROJECT NO. 3
      • Project Description
    • PROJECT NO. 4
      • Project Description
    • PROJECT NO. 5
      • Project Description
    • PROJECT NO. 6
      • Project Description
    • PROJECT NO. 7
      • Project Description
      • TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • IMMUNOPASSIVATION AND IMMUNOMODULATION
    • IMMUNOMODULATION
    • CELL ENCAPSULATION
    • TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 5 TISSUE ENGINEERING AND REGENERATION MARKET ANALYSIS BY MATERIALS

  • TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, THROUGH 2019 ($ MILLIONS)
  • SYNTHETIC MATERIALS
  • TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • BIODEGRADABLE SYNTHETIC POLYMERS
    • TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION
    • TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • MEDICAL POLY LACTIC ACID SCAFFOLD
    • TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS
    • TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • ARTIFICIAL VASCULAR GRAFT MATERIALS
      • Stem Cell Integration in Vascular Tissue Engineering
        • Extracellular Matrix ECM-Based Vascular Grafts
        • Cell Sheets without Scaffold Support 6
        • TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • HYDROGEL TECHNOLOGY
    • TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • BIOLOGICALLY DERIVED MATERIALS
  • TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • COLLAGEN
    • TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BYREGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
      • Animal-Derived
      • Recombinant
    • XENOGENIC TISSUE
    • TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • GENETICALLY ENGINEERED MATERIALS
  • TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • DEOXYRIBONUCLEIC ACID TRANSFECTION VECTORS
    • TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • GENETICALLY MANIPULATED CELLS
    • TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • THREE-DIMENSIONAL POLYMER TECHNOLOGY
    • TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • TRANGENICS
    • TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIBROBLASTS
    • TABLE 35 GLOBAL FIBROBLAST MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • NEURAL STEM CELLS
    • TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • GENE-ACTIVATED MATRICES
    • TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 ($ MILLIONS)

CHAPTER 6 TISSUE ENGINEERING AND REGENERATION MARKET BY APPLICATION

  • TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • INTERNAL ORGAN REGENERATION
  • TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • LIVER REGENERATION
    • TABLE 40 U.S. LIVER FAILURE STATISTICS, 2011
    • TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS
    • PANCREAS AND ISLET CELL REGENERATION
    • TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, 2010
    • KIDNEY AND RENAL TUBULE REGENERATION
    • TABLE 43 U.S. KIDNEY DISEASE STATISTICS, 2010
    • ORTHOPEDIC APPLICATIONS 8
    • TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION
    • TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • BONE REPAIR AND REPLACEMENT
    • TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 (MILLIONS)
    • CARTILAGE AND CONNECTIVE TISSUE DAMAGE TREATMENT
    • TISSUE-ENGINEERED PRODUCTS FOR BONE DEFECTS
    • CARTILAGE REPAIR AND REPLACEMENT
    • TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, 2007
    • MENISCUS REPAIR AND REPLACEMENT
    • TENDON AND LIGAMENT REPAIR AND REPLACEMENT
  • TISSUE ENGINEERING FOR THE CENTRAL NERVOUS SYSTEM
  • TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM DISEASES
  • TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • NEUROSURGICAL
      • Cell Implants for Parkinson's Diseases
      • TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, 2011
      • Cell Transplants for Epilepsy Treatment
      • Stem Cell Therapy for Multiple Sclerosis
    • SPINAL CORD INJURY AND SPINAL DISC REPAIR AND REPLACEMENT
    • TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, 2011
      • Spinal Cord Injury Treatments
      • Tissue Engineering for Spinal Cord Injury
        • Cell Therapy for Spinal Cord Injury
        • Scaffold Approach for Spinal Cord Injury Treatment
  • TISSUE ENGINEERING FOR CARDIOVASCULAR DISORDERS
  • TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • PERIPHERAL VASCULAR DISEASE APPLICATIONS
    • CORONARY ARTERY DISEASE APPLICATIONS
      • Heart Valves and Tissue Engineering
      • Mechanical Heart Valves
      • Biological Heart Valves
      • TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013
  • DENTAL TISSUE ENGINEERING
  • TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • DERMATOLOGY TISSUE ENGINEERING
  • TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, 2011
  • TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, 2014
  • TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS
  • TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • WOUND MANAGEMENT
    • TABLE 58 WOUND CARE MARKET BY CATEGORY (%)
      • Burn Treatment
      • Ulcer Treatment
    • ANTI-AGING THERAPIES
  • OTHERS
  • TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
    • MUSCLE REGENERATION
    • TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING
    • PERIPHERAL NERVE REPAIR
    • HERNIA AND SOFT TISSUE REPAIR

CHAPTER 7 TISSUE ENGINEERING AND REGENERATION MARKET BY REGION

  • TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 ($ MILLIONS)
  • TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • NORTH AMERICA
  • TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013
  • TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
  • U.S. SKIN TISSUE ENGINEERING PRODUCT MARKET
  • TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011
    • U.S. CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET
    • TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011
    • U.S. TISSUE ENGINEERING PRODUCTS FOR CARDION VASCULAR DISORDERS MARKET
    • TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND 2011
  • EUROPE
  • TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%)
  • TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%)
  • TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011
  • TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013
  • TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
    • EUROPEAN AND BONE TISSUE ENGINEERING PRODUCT MARKET
    • TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY
    • EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET
    • TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, 2011
    • TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES)
    • EUROPEAN TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISORDERS MARKET
    • TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2011
    • TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011
    • TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY,
    • TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES
    • EUROPEAN TISSUE ENGINEERING FOR INTERNAL ORGANS MARKET
    • ASIA-PACIFIC
    • FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE
    • TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
    • ASIA-PACIFIC CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET
    • ASIA-PACIFIC MARKET FOR CARDIOVASCULAR TISSUE ENGINEERING PRODUCTS
    • ASIA-PACIFIC SKIN TISSUE ENGINEERING PRODUCT MARKET
  • REST OF THE WORLD
  • TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, 2011
  • TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
    • REST OF THE WORLD CARTILAGE AND BONE TISSUE ENGINEERING PRODUCT MARKET
    • REST OF WORLD TISSUE ENGINEERING PRODUCTS FOR CARDIOVASCULAR DISORDERS MARKET
    • TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, 2011
    • TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY
    • REST OF THE WORLD TISSUE ENGINEERING PRODUCTS FOR CENTRAL NERVOUS SYSTEM-RELATED INJURIES AND DISEASES MARKET
    • TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS, 2011

CHAPTER 8 COMPETITIVE LANDSCAPE

  • FIGURE 6 KEY COMPETITIVE STRATEGIES*, 2010-2014 (%)
  • TABLE 86 KEY COMPETITIVE STRATEGIES, 2010-2014 (%)
  • APPROVAL
  • FIGURE 7 APPROVAL STRATEGY BY COMPANY, 2010-2014 (%)
  • TABLE 87 APPROVAL STRATEGIES BY COMPANY, 2010-2014 (NO./%)
  • TABLE 88 KEY APPROVALS, 2010-2014
  • AGREEMENTS, MERGERS AND ACQUISITIONS
  • FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, 2010-2014 (%)
  • TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, 2010-2014 (%)
  • TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010-2014
  • PRODUCT LAUNCHES AND CLINICAL TRIALS
  • FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)
  • TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)
  • TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND 2014

CHAPTER 9 PATENT ANALYSIS

  • TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)
  • FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)
  • U.S. PATENT ANALYSIS BY MARKET PARTICIPANT
  • TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • U.S. PATENT ANALYSIS BY APPLICATIONS
  • TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT
  • TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • EUROPEAN PATENT ANALYSIS BY APPLICATIONS
  • TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • JAPANESE PATENT ANALYSIS BY APPLICATION
  • TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)

CHAPTER 10 COMPANY PROFILES

  • ADVANCED BIOHEALING (A SHIRE PHARMACEUTICAL COMPANY)
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS
    • TABLE 100 ADVANCED BIOHEALING FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • ADVANCED CELL TECHNOLOGY INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS
  • ARTERIOCYTE
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS
  • ATHERSYS INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS
    • TABLE 104 ATHERSYS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • BIOHEART INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS
  • CERAPEDICS INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS
  • CO.DON AG
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 107 CO.DON AG RECENT DEVELOPMENTS
  • COOK MEDICAL INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS
  • CRYOLIFE INC
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS
  • CYTOGRAFT TISSUE ENGINEERING
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS
  • CYTOMEDIX INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS
  • CYTORI THERAPEUTICS INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS
    • TABLE 113 CYTORI THERAPEUTICS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • GENZYME (A SANOFI COMPANY)
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 114 GENZYME RECENT DEVELOPMENTS
    • TABLE 115 GENZYME FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • KINETIC CONCEPTS INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS
    • TABLE 117 KINETICS CONCEPTS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • MESOBLAST LTD.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • ORGANOGENESIS INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
  • ORTHOPEUTICS
  • WRIGHT MEDICAL TECHNOLOGY INC.
    • TISSUE ENGINEERING PRODUCT PORTFOLIO
    • TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS
    • TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, 2011-2013 ($ MILLIONS/%)

CHAPTER 11 PATENTS

  • TABLE 120 NORTH AMERICAN PATENTS
  • TABLE 121 EUROPEAN PATENTS
  • TABLE 122 JAPANESE PATENTS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 REGULATORY APPROVAL DIFFERENCES BETWEEN THE U.S. AND EUROPE
  • TABLE 2 HEALTHCARE PROVISIONS BY COUNTRY, 2014
  • TABLE 3 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING
  • TABLE 4 U.S. CLINICAL TRIALS FOR TISSUE ENGINEERING
  • TABLE 5 U.S. TERMINATED CLINICAL TRIALS
  • TABLE 6 EUROPEAN CLINICAL TRIALS FOR TISSUE ENGINEERING
  • TABLE 7 U.S. UNINTENTIONAL INJURIES FACTS, 2013 (NO./%)
  • TABLE 8 REGENERATIVE MEDICINE INDUSTRY TRENDS, 2007-2011
  • TABLE 9 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY TECHNOLOGY, THROUGH 2019 ($ MILLIONS)
  • TABLE 10 GLOBAL STEM CELL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 11 COMMONLY USED VEHICLES FOR STEM CELL DELIVERY
  • TABLE 12 COMMERCIALIZED TISSUE ENGINEERING PRODUCT SALES, 2011 ($ MILLIONS)
  • TABLE 13 GLOBAL CELL CULTURE TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 14 GLOBAL IMMUNOPASSIVATION AND IMMUNOMODULATION TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY MATERIAL, THROUGH 2019 ($ MILLIONS)
  • TABLE 16 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 GLOBAL SYNTHETIC TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 18 BIODEGRADABLE POLYMER CLASSIFICATION
  • TABLE 19 GLOBAL BIODEGRADABLE SYNTHETIC POLYMER MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 20 COMMERCIAL POLYMERIC SCAFFOLD PRODUCTS
  • TABLE 21 GLOBAL SCAFFOLD MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 22 GLOBAL ARTIFICIAL VASCULAR GRAFT MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 GLOBAL HYDROGEL TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 24 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 25 GLOBAL BIOLOGICALLY DERIVED TISSUE ENGINEERING AND REGENERATION MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BYREGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 GLOBAL BIOLOGICALLY DERIVED COLLAGEN MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 GLOBAL BIOLOGICALLY DERIVED XENOGENIC TISSUE MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL GENETICALLY ENGINEERED MATERIAL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 GLOBAL DEOXYRIBONUCLEIC ACID TRANSFECTION VECTOR MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 GLOBAL GENETICALLY MANIPULATED CELL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 33 GLOBAL THREE-DIMENSIONAL POLYMER TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 34 GLOBAL TRANSGENIC TECHNOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 35 GLOBAL FIBROBLAST MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 GLOBAL NEURAL STEM CELL MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 37 GLOBAL GENE-ACTIVATED MATRIX MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 38 GLOBAL TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 39 GLOBAL INTERNAL ORGAN REGENERATION APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 40 U.S. LIVER FAILURE STATISTICS, 2011
  • TABLE 41 ARTIFICIAL LIVER SUPPORT SYSTEMS
  • TABLE 42 U.S. PANCREATIC CANCER AND DIABETES STATISTICS, 2010
  • TABLE 43 U.S. KIDNEY DISEASE STATISTICS, 2010
  • TABLE 44 KEY FACTS REGARDING ORTHOPEDIC DISEASES, BY REGION
  • TABLE 45 GLOBAL ORTHOPEDIC APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 46 BONE DAMAGE AND RELATED DISEASES, 2011 (MILLIONS)
  • TABLE 47 GLOBAL CARTILAGE DAMAGE STATISTICS, 2007
  • TABLE 48 GLOBAL TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 49 GLOBAL NEURODEGENERATIVE DISEASE STATISTICS, 2011
  • TABLE 50 GLOBAL SPINAL CORD INJURY STATISTICS, 2011
  • TABLE 51 GLOBAL CARDIOVASCULAR DISORDERS APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 52 COMPANIES DEVELOPING CELL THERAPIES FOR CARDIO VASCULAR DISORDERS, 2013
  • TABLE 53 GLOBAL DENTAL TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 54 U.S. AND GLOBAL SKIN DAMAGE MEDICAL CONDITION STATISTICS, 2011
  • TABLE 55 COMMERCIALIZED ACELLULAR SKIN TISSUE-ENGINEERED, 2014
  • TABLE 56 COMMERCIALIZED CELLULAR SKIN TISSUE ENGINEERED PRODUCTS
  • TABLE 57 GLOBAL DERMATOLOGY TISSUE ENGINEERING APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 58 WOUND CARE MARKET BY CATEGORY (%)
  • TABLE 59 GLOBAL OTHER APPLICATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 60 IN VITRO VERSUS IN VIVO SKELETAL MUSCLE TISSUE ENGINEERING
  • TABLE 61 COMPANIES OPERATING IN REGENERATIVE MEDICINES MARKET BY CONTINENT, 2011 ($ MILLIONS)
  • TABLE 62 GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 63 NORTH AMERICAN COMMERCIALIZED TISSUE ENGINEERING PRODUCTS, 2013
  • TABLE 64 NORTH AMERICAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 65 U.S. SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE, 2011
  • TABLE 66 U.S. BONE DAMAGE AND RELATED DISEASE STATISTICS, 2011
  • TABLE 67 U.S. CARDIOVASCULAR DISORDER STATISTICS, 2010 AND 2011
  • TABLE 68 TISSUE ENGINEERING FIRMS BY TYPE, 2012 (%)
  • TABLE 69 EUROPEAN TISSUE ENGINEERING FIRMS BY REGION, 2012 (%)
  • TABLE 70 EUROPEAN SKIN DAMAGE CONDITIONS REQUIRING WOUND CARE STATISTICS, 2011
  • TABLE 71 EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN TISSUE-ENGINEERED PRODUCTS, 2013
  • TABLE 72 EUROPEAN TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 73 EUROPEAN BONE DAMAGE AND RELATED DISEASE MARKET BY COUNTRY
  • TABLE 74 EUROPEAN CARDIOVASCULAR DISORDER STATISTICS, 2011
  • TABLE 75 EUROPEAN RATE OF DEATH FROM HEART DISEASE BY COUNTRY, 2011 (DEATHS PER 100,000 CASES)
  • TABLE 76 EUROPEAN CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES, 2011
  • TABLE 77 EUROPEAN SPINAL CORD INJURY AND PARKINSON'S DISEASE BY COUNTRY, 2011
  • TABLE 78 EUROPEAN STEM CELL POLICIES BY COUNTRY,
  • TABLE 79 EUROPEAN COMPANIES DEVELOPING PRODUCTS IN TISSUE ENGINEERING AND REGENERATION FOR CENTRAL NERVOUS SYSTEM DISORDERS AND INJURIES
  • TABLE 80 ASIA-PACIFIC TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 81 GLOBAL SKIN-RELATED MEDICAL CONDITION STATISTICS, 2011
  • TABLE 82 REST OF WORLD TISSUE ENGINEERING AND REGENERATION APPLICATION MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 83 GLOBAL CARDIOVASCULAR DISORDER STATISTICS, 2011
  • TABLE 84 REST OF THE WORLD COMPANIES THAT MANUFACTURE AND DEVELOP TISSUE-ENGINEERED PRODUCTS FOR CARDIOVASCULAR DISORDER, BY COUNTRY
  • TABLE 85 GLOBAL CENTRAL NERVOUS SYSTEM DISORDER AND INJURY STATISTICS, 2011
  • TABLE 86 KEY COMPETITIVE STRATEGIES, 2010-2014 (%)
  • TABLE 87 APPROVAL STRATEGIES BY COMPANY, 2010-2014 (NO./%)
  • TABLE 88 KEY APPROVALS, 2010-2014
  • TABLE 89 AGREEMENTS, MERGERS AND ACQUISITIONS BY COMPANY, 2010-2014 (%)
  • TABLE 90 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010-2014
  • TABLE 91 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)
  • TABLE 92 KEY AGREEMENTS, MERGERS AND ACQUISITIONS, 2010 AND 2014
  • TABLE 93 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)
  • TABLE 94 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • TABLE 95 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • TABLE 96 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • TABLE 97 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • TABLE 98 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • TABLE 99 ADVANCED BIOHEALING RECENT DEVELOPMENTS
  • TABLE 100 ADVANCED BIOHEALING FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 101 ADVANCED CELL TECHNOLOGY INC. RECENT DEVELOPMENTS
  • TABLE 102 ARTERIOCYTE RECENT DEVELOPMENTS
  • TABLE 103 ATHERSYS INC. RECENT DEVELOPMENTS
  • TABLE 104 ATHERSYS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 105 BIOHEART INC. RECENT DEVELOPMENTS
  • TABLE 106 CERAPEDICS INC. RECENT DEVELOPMENTS
  • TABLE 107 CO.DON AG RECENT DEVELOPMENTS
  • TABLE 108 COOK MEDICAL INC. RECENT DEVELOPMENTS
  • TABLE 109 CRYO LIFE INC. RECENT DEVELOPMENTS
  • TABLE 110 CYTOGRAFT TISSUE ENGINEERING RECENT DEVELOPMENTS
  • TABLE 111 CYTOMEDIX INC. RECENT DEVELOPMENTS
  • TABLE 112 CYTORI THERAPEUTICS INC. RECENT DEVELOPMENTS
  • TABLE 113 CYTORI THERAPEUTICS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 114 GENZYME RECENT DEVELOPMENTS
  • TABLE 115 GENZYME FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 116 KINETIC CONCEPTS INC. RECENT DEVELOPMENTS
  • TABLE 117 KINETICS CONCEPTS FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 118 WRIGHT MEDICAL TECHNOLOGY INC. RECENT DEVELOPMENTS
  • TABLE 119 WRIGHT MEDICAL TECHNOLOGY FINANCIALS, 2011-2013 ($ MILLIONS/%)
  • TABLE 120 NORTH AMERICAN PATENTS
  • TABLE 121 EUROPEAN PATENTS
  • TABLE 122 JAPANESE PATENTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL TISSUE ENGINEERING AND REGENERATION MARKET BY REGION, 2013-2019 ($ MILLIONS)
  • FIGURE 1 TISSUE-ENGINEERING STRATEGIES
  • FIGURE 2 POTENTIAL NANOTECHNOLOGY APPLICATIONS
  • FIGURE 3 PORTER'S FIVE FORCE MODEL FOR TISSUE ENGINEERING PRODUCTS
  • FIGURE 4 GROWTH IN DISEASE TREATED VERSUS CLINICAL TRIALS, 2008-2012 (NO. OF TRIALS AND TREATMENTS)
  • FIGURE 5 PATHWAY FOR DISSEMINATION OF REGENERATIVE MEDICINE
  • FIGURE 6 KEY COMPETITIVE STRATEGIES*, 2010-2014 (%)
  • FIGURE 7 APPROVAL STRATEGY BY COMPANY, 2010-2014 (%)
  • FIGURE 8 AGREEMENTS, MERGERS AND ACQUISITIONS, BY COMPANY, 2010-2014 (%)
  • FIGURE 9 PRODUCT LAUNCHES AND CLINICAL TRIALS BY COMPANY, 2010-2014 (%)
  • FIGURE 10 REGISTERED AND APPROVED PATENTS BY COUNTRY, 2011-2014 (%)
  • FIGURE 11 U.S. PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • FIGURE 12 U.S. PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • FIGURE 13 EUROPEAN PATENT ANALYSIS BY MARKET PARTICIPANT, 2011-2014 (%)
  • FIGURE 14 EUROPEAN PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
  • FIGURE 15 JAPANESE PATENT ANALYSIS BY APPLICATION, 2011-2014 (%)
Back to Top